Which has preferable valuation & earnings, FLNA or IMUX?

Immunic is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$0.87 N/A Immunic N/A N/A -$97.17M -$4.38 N/A

Is FLNA or IMUX more profitable?

Cassava Sciences' return on equity of -58.78% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Immunic N/A -157.89% -107.88%

Does the media refer more to FLNA or IMUX?

In the previous week, Immunic had 19 more articles in the media than Cassava Sciences. MarketBeat recorded 21 mentions for Immunic and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat Immunic's score of 0.82 indicating that Cassava Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunic 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, NERV or FLNA?

Cassava Sciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Neurosciences N/A N/A -$293.42M -$28.87 N/A Cassava Sciences N/A N/A -$90.97M -$0.87 N/A

Is NERV or FLNA more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -31.72% Cassava Sciences N/A -58.78% -36.74%

Does the media prefer NERV or FLNA?

In the previous week, Minerva Neurosciences had 14 more articles in the media than Cassava Sciences. MarketBeat recorded 16 mentions for Minerva Neurosciences and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat Minerva Neurosciences' score of -0.02 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend FLNA or SBTX?

Cassava Sciences presently has a consensus target price of $5.00, suggesting a potential upside of 447.47%. Given Cassava Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cassava Sciences is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, FLNA or SBTX?

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cassava Sciences N/A N/A -$90.97M -$0.87 N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is FLNA or SBTX more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Cassava Sciences N/A -58.78% -36.74% Silverback Therapeutics N/A -29.62% -28.20%

Does the media prefer ACOG or FLNA?

In the previous week, Alpha Cognition had 7 more articles in the media than Cassava Sciences. MarketBeat recorded 9 mentions for Alpha Cognition and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat Alpha Cognition's score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer DERM or FLNA?

In the previous week, Journey Medical had 22 more articles in the media than Cassava Sciences. MarketBeat recorded 24 mentions for Journey Medical and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat Journey Medical's score of 0.07 indicating that Cassava Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Journey Medical 2 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cassava Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cassava Sciences (FLNA) Competitors

$0.91 -0.03 (-3.45%)

As of 08/14/2026 04:00 PM Eastern

Compare

FLNA vs. IMUX, NERV, SBTX, ACOG, and DERM

Should you buy Cassava Sciences stock or one of its competitors? Cassava Sciences's main competitors and comparable companies include Immunic (IMUX), Minerva Neurosciences (NERV), Silverback Therapeutics (SBTX), Alpha Cognition (ACOG), and Journey Medical (DERM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cassava Sciences compare to Immunic?

Cassava Sciences (NASDAQ:FLNA) and Immunic (NASDAQ:IMUX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

In the previous week, Immunic had 19 more articles in the media than Cassava Sciences. MarketBeat recorded 21 mentions for Immunic and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat Immunic's score of 0.82 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunic	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cassava Sciences has a beta of -0.7, suggesting that its stock price is 170% less volatile than the broader market. Comparatively, Immunic has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

Cassava Sciences' return on equity of -58.78% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Immunic	N/A	-157.89%	-107.88%

Immunic is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A

38.0% of Cassava Sciences shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by insiders. Comparatively, 5.5% of Immunic shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cassava Sciences presently has a consensus target price of $5.00, suggesting a potential upside of 447.47%. Immunic has a consensus target price of $47.57, suggesting a potential upside of 196.21%. Given Cassava Sciences' higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00

Summary

Cassava Sciences and Immunic tied by winning 7 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Minerva Neurosciences presently has a consensus price target of $10.33, indicating a potential upside of 125.62%. Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 447.47%. Given Cassava Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Minerva Neurosciences had 14 more articles in the media than Cassava Sciences. MarketBeat recorded 16 mentions for Minerva Neurosciences and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat Minerva Neurosciences' score of -0.02 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Minerva Neurosciences' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
Cassava Sciences	N/A	-58.78%	-36.74%

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cassava Sciences is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Minerva Neurosciences has a beta of -0.1, indicating that its stock price is 110% less volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.7, indicating that its stock price is 170% less volatile than the broader market.

Summary

Cassava Sciences beats Minerva Neurosciences on 7 of the 12 factors compared between the two stocks.

How does Cassava Sciences compare to Silverback Therapeutics?

Cassava Sciences (NASDAQ:FLNA) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Silverback Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Silverback Therapeutics' return on equity of -29.62% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
Silverback Therapeutics	N/A	-29.62%	-28.20%

38.0% of Cassava Sciences shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Cassava Sciences presently has a consensus target price of $5.00, suggesting a potential upside of 447.47%. Given Cassava Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cassava Sciences is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cassava Sciences has a beta of -0.7, meaning that its stock price is 170% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

In the previous week, Cassava Sciences had 2 more articles in the media than Silverback Therapeutics. MarketBeat recorded 2 mentions for Cassava Sciences and 0 mentions for Silverback Therapeutics. Cassava Sciences' average media sentiment score of 0.93 beat Silverback Therapeutics' score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cassava Sciences	Positive
Silverback Therapeutics	Neutral

Summary

Cassava Sciences beats Silverback Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Cassava Sciences compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Alpha Cognition has higher revenue and earnings than Cassava Sciences. Alpha Cognition is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	18.83	-$20.67M	-$1.35	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Cassava Sciences has a net margin of 0.00% compared to Alpha Cognition's net margin of -153.61%. Alpha Cognition's return on equity of -55.04% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-153.61%	-55.04%	-43.38%
Cassava Sciences	N/A	-58.78%	-36.74%

38.0% of Cassava Sciences shares are owned by institutional investors. 8.6% of Alpha Cognition shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Alpha Cognition has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.7, indicating that its stock price is 170% less volatile than the broader market.

In the previous week, Alpha Cognition had 7 more articles in the media than Cassava Sciences. MarketBeat recorded 9 mentions for Alpha Cognition and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat Alpha Cognition's score of 0.00 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Cognition currently has a consensus target price of $16.75, indicating a potential upside of 89.48%. Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 447.47%. Given Cassava Sciences' higher probable upside, analysts plainly believe Cassava Sciences is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Alpha Cognition beats Cassava Sciences on 8 of the 15 factors compared between the two stocks.

How does Cassava Sciences compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Journey Medical has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.7, suggesting that its stock price is 170% less volatile than the broader market.

In the previous week, Journey Medical had 22 more articles in the media than Cassava Sciences. MarketBeat recorded 24 mentions for Journey Medical and 2 mentions for Cassava Sciences. Cassava Sciences' average media sentiment score of 0.93 beat Journey Medical's score of 0.07 indicating that Cassava Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	2 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cassava Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are owned by institutional investors. 14.5% of Journey Medical shares are owned by company insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Journey Medical has higher revenue and earnings than Cassava Sciences. Journey Medical is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$68.18M	2.71	-$11.43M	-$0.22	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Cassava Sciences has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-8.95%	-20.23%	-6.60%
Cassava Sciences	N/A	-58.78%	-36.74%

Journey Medical presently has a consensus target price of $14.00, indicating a potential upside of 108.33%. Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 447.47%. Given Cassava Sciences' higher possible upside, analysts clearly believe Cassava Sciences is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Journey Medical beats Cassava Sciences on 10 of the 15 factors compared between the two stocks.

Get Cassava Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLNA vs. The Competition

Export

Metric	Cassava Sciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$44.12M	$11.92B	$7.02B	$13.06B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-1.05	779.99	271.27	25.33
Price / Sales	N/A	749.72	583.72	76.93
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	0.69	11.60	12.92	6.25
Net Income	-$90.97M	$2.77B	$3.45B	$347.82M
7 Day Performance	-8.21%	0.14%	1.15%	1.08%
1 Month Performance	-16.97%	0.06%	1.37%	0.82%
1 Year Performance	-60.97%	145.15%	62.53%	20.99%

Cassava Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLNA Cassava Sciences	1.9134 of 5 stars	$0.91 -3.4%	$5.00 +447.5%	-62.1%	$44.12M	N/A	N/A	20
IMUX Immunic	2.746 of 5 stars	$14.01 +0.3%	$47.57 +239.6%	+75.2%	$190.83M	N/A	N/A	70	Trending News Earnings Report Analyst Upgrade Analyst Revision
NERV Minerva Neurosciences	1.6643 of 5 stars	$4.06 +1.9%	$10.50 +158.9%	+152.3%	$189.95M	N/A	N/A	9	News Coverage Earnings Report Analyst Downgrade Analyst Revision Gap Up
SBTX Silverback Therapeutics	N/A	$5.13 -8.9%	N/A	-61.4%	$184.98M	N/A	N/A	83	Gap Down High Trading Volume
ACOG Alpha Cognition	4.5035 of 5 stars	$8.25 -0.4%	$16.00 +93.9%	+10.5%	$179.60M	$10.22M	N/A	N/A	News Coverage Earnings Report Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLNA) was last updated on 8/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cassava Sciences (FLNA) Competitors

FLNA vs. IMUX, NERV, SBTX, ACOG, and DERM

How does Cassava Sciences compare to Immunic?

Summary

How does Cassava Sciences compare to Minerva Neurosciences?

Summary

How does Cassava Sciences compare to Silverback Therapeutics?

Summary

How does Cassava Sciences compare to Alpha Cognition?

Summary

How does Cassava Sciences compare to Journey Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cassava Sciences (FLNA) Competitors

FLNA vs. IMUX, NERV, SBTX, ACOG, and DERM

How does Cassava Sciences compare to Immunic?

Does the media refer more to FLNA or IMUX?

Which has more volatility & risk, FLNA or IMUX?

Is FLNA or IMUX more profitable?

Which has preferable valuation & earnings, FLNA or IMUX?

Do institutionals and insiders believe in FLNA or IMUX?

Do analysts prefer FLNA or IMUX?

Summary

How does Cassava Sciences compare to Minerva Neurosciences?

Do analysts recommend NERV or FLNA?

Does the media prefer NERV or FLNA?

Is NERV or FLNA more profitable?

Do insiders and institutionals believe in NERV or FLNA?

Which has better valuation & earnings, NERV or FLNA?

Which has more volatility & risk, NERV or FLNA?

Summary

How does Cassava Sciences compare to Silverback Therapeutics?

Which has preferable earnings & valuation, FLNA or SBTX?

Is FLNA or SBTX more profitable?

Do institutionals & insiders hold more shares of FLNA or SBTX?

Do analysts recommend FLNA or SBTX?

Which has more volatility & risk, FLNA or SBTX?

Does the media refer more to FLNA or SBTX?

Summary

How does Cassava Sciences compare to Alpha Cognition?

Which has preferable earnings and valuation, ACOG or FLNA?

Is ACOG or FLNA more profitable?

Do institutionals and insiders have more ownership in ACOG or FLNA?

Which has more risk and volatility, ACOG or FLNA?

Does the media prefer ACOG or FLNA?

Do analysts prefer ACOG or FLNA?

Summary

How does Cassava Sciences compare to Journey Medical?

Which has more volatility and risk, DERM or FLNA?

Does the media prefer DERM or FLNA?

Do institutionals and insiders have more ownership in DERM or FLNA?

Which has preferable valuation & earnings, DERM or FLNA?

Is DERM or FLNA more profitable?

Do analysts recommend DERM or FLNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools